Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT04385589

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04385589
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04385589. Randomized; double masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2020-12-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
insulin
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct04385589
Content hash
ba59aa45bbedee8302de47b4b86263feee944f9bd132bfd89b7739828df5c48d